Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

INDUSTRY 4 OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, Large B-Cell, Diffuse 7 Leukemia, Lymphocytic, Chronic, B-Cell 5 Lymphoma, Mantle-Cell 4 Lymphoma, B-Cell 4 Lymphoma, Follicular 3 Lymphoma, B-Cell, Marginal Zone 3 Lymphoma 3 Lymphoma, Non-Hodgkin 2 Recurrence 1 Leukemia, Prolymphocytic 1 Hodgkin Disease 1 Burkitt Lymphoma 1

Interventions

Cyclophosphamide 115 Dexamethasone 70 fludarabine phosphate 57 Cytarabine 56 fludarabine 52 Rituximab 51 Peripheral Blood Stem Cell Transplantation 40 Etoposide 40 Gemcitabine 39 Lenalidomide 38 pembrolizumab 33 Radiotherapy 33 Busulfan 33 Filgrastim 32 Carboplatin 31 Methotrexate 30 Cyclosporine 29 Cisplatin 29 Bortezomib 29 Mycophenolic Acid 28 Melphalan 28 venetoclax 27 Paclitaxel 26 Whole-Body Irradiation 24 Antilymphocyte Serum 23 Temozolomide 22 Granulocyte Colony-Stimulating Factor 20 Calcium Dobesilate 20 Bevacizumab 20 Tacrolimus 19

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Recurrence × tafasitamab × Clear all

NCT07126236 2025-08-17

REPIFIR

Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea

Phase 2 Recruiting

Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon ⚡